IMP-3 Promotes Migration and Invasion of Melanoma Cells by Modulating the Expression of HMGA2 and Predicts Poor Prognosis in Melanoma

Journal of Investigative Dermatology

Volumn 135, Issue 4, 2015, Pages 1065-1073

  Sheen, Yi Shuan ^a   Liao, Yi Hua ^a   Lin, Ming Hsien ^b,c   Chu, Chia Ying ^c   Ho, Bing Ying ^a   Hsieh, Meng Chen ^a   Chen, Pin Chun ^a   Cha, Shih Ting ^c   Jeng, Yung Ming ^a   Chang, Cheng Chi ^c   Chiu, Hsien Ching ^a   Jee, Shiou Hwa ^a   Kuo, Min Liang ^c   Chu, Chia Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; IMP3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ACRAL LENTIGINOUS MELANOMA; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL MOTION; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PROGNOSIS; RISK; SKIN TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA-BINDING PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925455121     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.480     Document Type: Article

References (24)

1. Assi J, Srivastava G, Matta A et al. (2013) Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence. PLoS One 8:e74437
2. Berlingieri MT, Manfioletti G, Santoro M et al. (1995) Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 15:1545-53
3. Fedele M, Battista S, Manfioletti G et al. (2001) Role of the high mobility group A proteins in human lipomas. Carcinogenesis 22:1583-91
4. Frewer KA, Sanders AJ, Owen S et al. (2013) A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics Proteomics 10:187-96
5. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-7
6. Jeng YM, Chang CC, Hu FC et al. (2008) RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48:1118-27
7. Jonson L, Christiansen J, Hansen TV et al. (2014) IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell Rep 7:539-51
8. Kabbarah O, Nogueira C, Feng B et al. (2010) Integrative genome comparison of primary and metastatic melanomas. PLoS One 5:e10770
9. Liao B, Hu Y, Herrick DJ et al. (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280:18517-24
10. Ma GF, Miao Q, Zeng XQ et al. (2013) Transforming growth factor-beta1 and -beta2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro. PLoS One 8:e54249
11. Miller AJ, Mihm MC Jr. (2006) Melanoma. N Engl J Med 355:51-65
12. Mueller-Pillasch F, Lacher U, Wallrapp C et al. (1997) Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14:2729-33
13. Mueller-Pillasch F, Pohl B, Wilda M et al. (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88:95-9
14. Nessling M, Richter K, Schwaenen C et al. (2005) Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 65:439-47
15. Nielsen J, Christiansen J, Lykke-Andersen J et al. (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19:1262-70
16. Nielsen J, Kristensen MA, Willemoes M et al. (2004) Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability. Nucleic Acids Res 32:4368-76
17. Pryor JG, Bourne PA, Yang Q et al. (2008) IMP-3 is a novel progression marker in malignant melanoma. Modern Pathol 21:431-7
18. Raskin L, Fullen DR, Giordano TJ et al. (2013) Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol 133:2585-92
19. Si L, Kong Y, Xu X et al. (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48:94-100
20. Suvasini R, Shruti B, Thota B et al. (2011) Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 286:25882-90
21. Tureci O, Sahin U, Koslowski M et al. (2002) A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene 21:3879-88
22. Wang L, Qin H, Li L et al. (2012) Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas. Med Oncol 29:3491-7
23. Yu L, Xu H, Wasco MJ et al. (2010) IMP-3 expression in melanocytic lesions. J Cutan Pathol 37:316-22
24. Zhou X, Benson KF, Ashar HR et al. (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376:771-4